HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Timo L M Ten Hagen Selected Research

Liposomes (Liposome)

10/2022Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience.
10/2022Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: Towards bypassing EPR.
2/2022Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.
12/2021Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.
8/2020Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles.
3/2020Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation.
1/2019Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.
10/2017Inhomogeneous crystal grain formation in DPPC-DSPC based thermosensitive liposomes determines content release kinetics.
10/2016EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.
4/2016A Novel Combined Approach of Short-Chain Sphingolipids and Thermosensitive Liposomes for Improved Drug Delivery to Tumor Cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Timo L M Ten Hagen Research Topics

Disease

57Neoplasms (Cancer)
11/2023 - 11/2002
16Melanoma (Melanoma, Malignant)
04/2021 - 07/2003
10Hyperthermia
10/2023 - 06/2011
7Breast Neoplasms (Breast Cancer)
12/2022 - 05/2010
5Neoplasm Metastasis (Metastasis)
01/2023 - 08/2011
5Sarcoma (Soft Tissue Sarcoma)
08/2020 - 07/2005
4Colorectal Neoplasms (Colorectal Cancer)
11/2016 - 04/2015
2Carcinogenesis
01/2023 - 11/2012
2Squamous Cell Carcinoma of Head and Neck
01/2020 - 01/2016
2Head and Neck Neoplasms (Head and Neck Cancer)
01/2020 - 01/2013
2Necrosis
04/2006 - 11/2002
1Uterine Cervical Neoplasms (Cancer of the Cervix)
10/2023
1Thyroid Neoplasms (Thyroid Cancer)
02/2022
1Eye Diseases (Eye Disease)
03/2020
1Uterine Cervical Dysplasia
01/2016
1Basal Cell Carcinoma (Rodent Ulcer)
01/2016

Drug/Important Bio-Agent (IBA)

21Liposomes (Liposome)IBA
10/2022 - 11/2002
9Doxorubicin (Adriamycin)FDA LinkGeneric
04/2021 - 11/2013
7LipidsIBA
10/2022 - 08/2015
5Proteins (Proteins, Gene)FDA Link
01/2023 - 05/2010
5Peptides (Polypeptides)IBA
02/2022 - 05/2014
51-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2022 - 01/2014
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2014 - 11/2002
4AntigensIBA
04/2023 - 01/2016
4SphingolipidsIBA
08/2020 - 04/2015
4AntibodiesIBA
01/2020 - 05/2010
3Therapeutic UsesIBA
01/2020 - 03/2016
3ErbB Receptors (EGF Receptor)IBA
01/2020 - 07/2015
3Cetuximab (Erbitux)FDA Link
01/2020 - 07/2015
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2019 - 02/2012
3Phosphoric Monoester Hydrolases (Phosphatases)IBA
11/2016 - 04/2015
3liposomal doxorubicin (Doxil)FDA Link
03/2016 - 11/2013
2LigandsIBA
02/2022 - 10/2016
2Photosensitizing Agents (Photosensitizers)IBA
01/2022 - 01/2020
2AnthracyclinesIBA
01/2021 - 08/2015
2Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
01/2021 - 12/2015
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2019 - 01/2016
2Single-Chain AntibodiesIBA
01/2019 - 01/2016
2Phosphotransferases (Kinase)IBA
11/2016 - 04/2016
2Tissue Inhibitor of Metalloproteinase-3IBA
10/2016 - 01/2014
2Immunoglobulin Fab FragmentsIBA
10/2016 - 07/2015
2Conditioned Culture MediaIBA
01/2016 - 01/2014
2IntegrinsIBA
12/2015 - 06/2013
2Mitoxantrone (Novantrone)FDA LinkGeneric
08/2015 - 04/2015
2Somatostatin Receptors (Somatostatin Receptor)IBA
05/2014 - 01/2014
2Octreotide (Sandostatin)FDA LinkGeneric
05/2014 - 01/2014
2Melphalan (Alkeran)FDA LinkGeneric
06/2013 - 07/2005
2Interleukin-2 (IL2)IBA
02/2012 - 03/2011
1GadoliniumIBA
11/2023
1Metal-Organic FrameworksIBA
11/2023
1GoldIBA
11/2023
1DNA (Deoxyribonucleic Acid)IBA
10/2023
1Transferrin (beta 2 Transferrin)IBA
06/2023
1Epidermal Growth Factor (EGF)IBA
04/2023
1Neoplasm Antigens (Tumor Antigens)IBA
04/2023
1CarbohydratesIBA
04/2023
1Carcinoembryonic AntigenIBA
04/2023
1Tumor Biomarkers (Tumor Markers)IBA
04/2023
1Prostate-Specific Antigen (Semenogelase)IBA
04/2023
1Keratin-19 (Keratin 19)IBA
04/2023
1MicroRNAs (MicroRNA)IBA
01/2023
1Circular RNAIBA
01/2023
1CateninsIBA
01/2023
1Sirolimus (Rapamycin)FDA Link
12/2022
1PolymersIBA
10/2022
1SuspensionsIBA
08/2022
1Hormones (Hormone)IBA
08/2022
1piperineIBA
08/2022
1aspartic acid glycine arginineIBA
02/2022
1Cell-Penetrating PeptidesIBA
02/2022
1Trans-Activators (Trans-Acting Factor)IBA
02/2022
1Competitive Endogenous RNAIBA
02/2022
1Single-Domain AntibodiesIBA
01/2022
1Protein CoronaIBA
01/2022
1Coloring Agents (Dyes)IBA
01/2021
1SDDSIBA
01/2021
1phthalocyanineIBA
01/2020
1EpitopesIBA
01/2020
1Chimeric Antigen ReceptorsIBA
01/2020
1Caspase 3 (Caspase-3)IBA
01/2020
1HLA-A2 Antigen (HLA A2 Antigen)IBA
01/2020
1Oncogene Proteins (Oncogene Protein)IBA
12/2019
1rhoA GTP-Binding ProteinIBA
12/2019
1Dihydrotachysterol (AT 10)IBA
01/2019
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
11/2016
1phosphoinositide-3,4-bisphosphateIBA
11/2016
1Contrast MediaIBA
01/2016
1Drug CarriersIBA
01/2016
1p38 Mitogen-Activated Protein KinasesIBA
01/2016

Therapy/Procedure

19Therapeutics
11/2023 - 08/2011
9Drug Therapy (Chemotherapy)
08/2022 - 10/2007
4Immunotherapy
12/2021 - 07/2003
4Induced Hyperthermia (Thermotherapy)
01/2021 - 01/2016
3Radiotherapy
10/2023 - 11/2002
3Photochemotherapy (Photodynamic Therapy)
01/2022 - 01/2020
3Lasers (Laser)
01/2020 - 11/2002
2Injections
10/2021 - 10/2007
1Precision Medicine
11/2023
1Quantum Dots (Quantum Dot)
11/2023
1Communication Aids for Disabled (TDD)
01/2022